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1 |  INTRODUCTION
Memo1 is an evolutionary conserved protein in all kingdoms 
of life that has shown intracellular expression in cytoplasma 
and nucleus (Haenzi et al., 2014; Moor, Haenzi, et al., 2018; 
Schlatter et al., 2012). A conditional and inducible knockout 
mouse model with postnatal deletion of exon 2 of the Memo1 
gene has resulted in a syndrome of aging and premature death 
with traits such as elevated calcemia, elevated FGF23 and 
1,25(OH)2-vitamin D3, bone disease, lung emphysema, atro-
phy of subcutaneous fat, insulin hypersensitivity, and renal 
insufficiency (Haenzi et al., 2014; Moor, Ramakrishnan, 
et al., 2018). This phenotype significantly overlaps with phe-
notypes of mouse models deficient in KLOTHO (Kuro-o 
et al., 1997) or FGF23 (Shimada et al., 2004), two proteins 
which have tremendously reshaped our understanding of the 
regulation of calcium and phosphate metabolism by the kid-
ney and bone and to a lesser extent also the intestine (Hu, 
Shiizaki, Kuro-O, & Moe, 2013; Moor & Bonny, 2016).
In addition, evidence from cell culture experiments in-
vestigating co-localization and phosphorylation status of 
adaptor proteins suggested that mediator of cell motility 1 
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Abstract
Mediator of cell motility 1 (MEMO1) is a ubiquitously expressed modulator of cel-
lular responses to growth factors including FGF23 signaling, and Memo1-deficient 
mice share some phenotypic traits with Fgf23- or Klotho-deficient mouse models. 
Here, we tested whether Memo1 gene expression is regulated by calciotropic hor-
mones or by changing the dietary mineral load. MLO-Y4 osteocyte-like cells were 
cultured and treated with 1,25(OH)2-vitamin D3. Wild-type C57BL/6N mice under-
went treatments with 1,25(OH)2-vitamin D3, parathyroid hormone, 17β-estradiol 
or vehicle. Other cohorts of C57BL/6N mice were fed diets varying in calcium or 
phosphate content. Expression of Memo1 and control genes was assessed by qPCR. 
1,25(OH)2-vitamin D3 caused an acute decrease in Memo1 transcript levels in vitro, 
but not in vivo. None of the hormones tested had an influence on Memo1 transcripts, 
whereas the assessed control genes reacted the expected way. Dietary interventions 
with calcium and phosphate did not affect Memo1 transcripts but altered the chosen 
control genes’ expression. We observed that Memo1 was not regulated by calcio-
tropic hormones or change in mineral load, suggesting major differences between the 
regulation and physiological roles of Klotho, Fgf23, and Memo1.
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(MEMO1) protein participates in and modulates a signal-
ing cascade involving FGF23 and the FGFR (Haenzi et al., 
2014).
Serum analyses of Klotho and Fgf23-deficient mice 
showed excessive 1,25(OH)2-vitamin D3 levels, a finding that 
has been variably found in Memo1-deficient mice depend-
ing on the genetic background (Haenzi et al., 2014; Moor, 
Ramakrishnan, et al., 2018). The promoters of Fgf23 and 
Klotho both contain vitamin D response elements (VDRE) 
(Forster et al., 2011; Orfanidou, Malizos, Varitimidis, & 
Tsezou, 2012). FGF23 secretion is increased by parathyroid 
hormone (PTH) (Lavi-Moshayoff, Wasserman, Meir, Silver, 
& Naveh-Many, 2010) and 17β-estradiol (Carrillo-Lopez 
et al., 2009). Regarding the regulation of Memo1, a transcrip-
tomic analysis of rat pineal glands has detected increased 
Memo1 transcripts upon synthetic estrogen treatment com-
pared to controls (Deffenbacher & Shull, 2006), highlighting 
a potential endocrine regulation of the transcription of the 
Memo1 gene. Here, we, therefore, tested the hypothesis that 
Memo1 expression can be regulated by minerals or calcit-
ropic stimuli.
2 |  METHODS
2.1 | Cell culture
The mouse long bone osteocyte-Y4 cell line (MLO-Y4) 
was kindly provided by Lynda Bonewald (Kato, Windle, 
Koop, Mundy, & Bonewald, 1997). MLO-Y4 cells were 
maintained in culture in minimal essential medium alpha-
modified, alpha-MEM (Gibco by Life Technologies), 
containing 2.5% heat-inactivated calf serum (Sigma), 
2.5% heat-inactivated fetal bovine serum (Sigma), and 1% 
penicillin/streptomycin (Invitrogen by Life Technologies). 
Serum heat inactivation was carried out in water bath at 
56°C for 30 min. Cells were cultured on rat-tail type I col-
lagen (Invitrogen by Life Technologies). For vitamin D 
stimulation, cells were kept in serum-free medium sup-
plemented with 10 nM 1,25(OH)2-vitamin D3 (Sigma) or 
ethanol vehicle for 24 hr.
2.2 | Animal experiments
C57BL/6N mice were obtained from Janvier. Mice were held 
in a conventional animal facility with up to six animals per 
cage and they were fed a standard laboratory chow (Kliba 
Nafnag TS3242; calcium 1%, phosphorus 0.65%, magnesium 
0.23%, vitamin D 1,600 IU/kg, vitamin A 27,000 IU/kg, vi-
tamin E 150  mg/kg, protein 18.8%, crude fat 5.6%, crude 
fiber 3.5%, lysine 1.1%; KLIBA) unless specified otherwise 
and were kept on 12/12 (experimental) or 14/10 (breeding) 
light–dark cycles. All animal experimental protocols were 
approved by the State Veterinary Service of the Canton de 
Vaud, Switzerland. For all mouse studies, sample sizes were 
considered based on previous results in our laboratory.
2.3 | Dietary interventions
For studies of mineral metabolism, specifically designed 
diets and hormones were used. Calcium diet challenge ex-
periments were carried with five male C57BL/6N mice per 
condition in their home cage, all aged 12 weeks. Mice were 
randomly allocated to be fed modifications of KLIBA 2222 
diet containing either 0.17% (low calcium diet), 0.82% (nor-
mal calcium diet) or 1.69% (high calcium diet) (KLIBA, 
2222) over 7 days. All calcium diets contained phosphorus 
0.8%, vitamin A 4,000 IU/kg, vitamin D 1,000 IU/kg, vitamin 
E 100 mg/kg, protein 18%, and crude fat 7%, lysine 14 g/kg 
(Kliba, 2222). For a phosphate diet challenge, three groups of 
five male C57BL/6N mice all aged 13–14 weeks were kept 
in metabolic cages and randomly allocated to be fed diets 
containing low (0.2%), intermediate (0.8%), or high (1.5%) 
phosphate content over 7  days. The phosphate diets were 
modifications of KLIBA 2222 diet (calcium 1.2%, vitamin A 
4,000 IU/kg, vitamin D 1,000 IU/kg, vitamin E 100 mg/kg, 
protein 18%, crude fat 7%, and lysine 14 g/kg).
2.4 | Hormone injections
All hormone injections were performed in the home cage 
of the mice after random treatment allocation of individual 
ear-marked mice. For 1,25(OH)2-vitamin D3 treatment, male 
C57BL/6N mice aged 13–15  weeks were subcutaneously 
injected with 2  μg/kg body weight 1,25(OH)2-vitamin D3 
(Sigma D1530) in ethanol 1% in NaCl 0.9%. The dose and 
application route was the same as previously used in our lab-
oratory. Control mice were injected with 1% (v/v) ethanol in 
NaCl 0.9%. Mice were sacrificed 6 hr after injection.
For PTH treatment, male C57BL/6N mice aged 
12–13  weeks were subcutaneously injected with 80  μg/kg 
body weight human PTH fragment 1–34 (hPTH1-34) (Sigma 
P3796) in NaCl 0.9% or NaCl 0.9% alone as vehicle and sac-
rificed 2  hr after injection. The dose and application route 
used was determined from the literature (Kramer, Loots, 
Studer, Keller, & Kneissel, 2010).
For estradiol treatment, male C57BL/6N mice aged 
16 weeks received one daily subcutaneous injection of 15 μg 
17β-Estradiol (Sigma E8875) in ethanol 0.1% (v/v) in NaCl 
0.9% for five consecutive days and were sacrificed 4 hr after 
the last injection. The dose per body weight and the drug ap-
plication route was derived from the literature, as shown Van 
Abel et al. (2002) to induce Trpv5 expression. Control mice 
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were subcutaneously injected with 0.1% ethanol in NaCl 
0.9% for 5 days.
2.5 | Mouse dissection
For euthanasia, mice were intraperitoneally injected with 
0.1 mg/gBW of ketamine (Ketanarkon 100 Vet., Streuli) and 
0.02  mg/gBW of xylazine (Rompun, Bayer), followed by 
terminal exsanguination by orbital puncture under full anes-
thesia and/or by cervical dislocation. Organs were collected, 
kidneys were cut in half, and organs were snap frozen in liq-
uid nitrogen immediately, followed by storage at −80°C until 
further use.
2.6 | RNA extraction
RNA was extracted using TRI reagent (Applied Biosystems 
by Life Technologies) according to manufacturer's instruc-
tions. RNA pellets were dried and dissolved in RNase-free 
H2O. RNA concentration was measured photometrically 
using NanoDrop (NanoDrop 2000, Thermo Fisher Scientific). 
RNA A260/A280 ratio was assessed and each RNA sample 
was visualized on a 1% agarose gel.
RNA was reverse transcribed to cDNA using the 
PrimeScript RT reaction kit (Takara Bio Inc). RNA input 
quantities per sample were 1–2 μg for bone, 500 ng for kid-
ney or 1 μg of MLO-Y4 RNA. The resulting cDNA mix was 
diluted 2–12x depending on tissue type.
2.7 | qPCR
For quantitative gene transcript expression analysis, 2 μL of 
cDNA was used for SYBR Green qPCR (Applied Biosystems 
by Life Technologies) on a 7500 Fast machine (Applied 
Biosystems). Samples were run in triplicate in 20  μL total 
volume for each gene, and actin or GAPDH was used for 
normalization. Melting curves were obtained for every run. 
Program settings were: 95°C during 20  s, 40 cycles (95°C 
3 s, 60°C 30 s), and for melting curve stage: 95°C 15 s, 60°C 
1 min, rising at 1% ramp speed to 95°C (15 s), and 60°C 15 s. 
Data were analyzed using the delta-delta CT method. Primers 
were ordered from Microsynth (Switzerland) and sequences 
are shown in Table 1. All amplified products were visualized 
on agarose gels.
2.8 | Data analysis
Human Memo1 promoter sequences were analyzed in silico 
using the UCSC Genome Browser and Serial Cloner 2.6.1.
Data from experiments with two independent groups were 
analyzed by t test or Mann–Whitney U test. For comparison of 
three groups, Kruskal–Wallis test was used with Bonferroni's 
Multiple Comparison posttest. All statistical analyses were 
conducted using GraphPad PRISM 5.03. Two-sided p < .05 
were considered significant.
3 |  RESULTS
Memo1-deficient mice resemble by some traits Klotho mu-
tant and FGF23 KO mice (Haenzi et al., 2014), and the pro-
moters of Klotho and FGF23 harbor regulatory sequences 
that can be bound by vitamin D receptors (Forster et al., 
2011; Orfanidou et al., 2012). For these reasons, we deter-
mined the regulation of Memo1 gene expression by miner-
als and calciotropic hormones. We have previously shown 
that MLO-Y4 osteocyte-like cell line expressed Memo1 
transcripts and protein (Moor, Ramakrishnan, et al., 2018).
3.1 | Memo1 is diminished by 1,25(OH)2-
vitamin D3 in vitro but not in vivo
An in silico promoter analysis of the human Memo1 gene re-
vealed a conserved CpG island (Gardiner-Garden & Frommer, 
1987) sequence in the 1,000 bases in 5’ direction of transcrip-
tion start site of Memo1 that was considered as the putative pro-
moter sequence (Figure S1). In a screen for published VDREs, 
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we identified two incidences of a negative VDRE with the se-
quence 5′-GCTTTCC-3′ (Towers, Staeva, & Freedman, 1999). 
Five VDRE sequences reported elsewhere (Calle, Maestro, & 
Garcia-Arencibia, 2008; McGaffin & Chrysogelos, 2005; Roff 
& Wilson, 2008) were undetectable on either sense or antisense 
strand. Therefore, we proceeded to experimentally investigate 
the effects of stimulation with 10  nM 1,25(OH)2-vitamin D3 
on gene expression in MLO-Y4 cells (Figure 1). Known vita-
min D-dependent transcripts were first assessed. Transcripts 
of Cyp24a1 encoding a vitamin D inactivating hydroxlyase 
(Figure 1a) and of osteoclast regulator Rankl (Figure 1c) were 
increased upon 1,25(OH)2-vitamin D3 treatment, whereas tran-
scripts of FGF23 regulator Phex and expression of bone-derived 
hormone osteocalcin/bone gamma-carboxyglutamate (Bglap) 
were diminished (Figure 1b,d). Memo1 transcripts were reduced 
by 20% upon 1,25(OH)2-vitamin D3 treatment (Figure 1e).
Next, we intraperitoneally injected 1,25(OH)2-vitamin D3 
in mice. Six hours post-injection we harvested the kidney and 
tibia of these animals and investigated the mRNA levels of 
Memo1. Memo1 RNA levels remained unchanged in the kidney 
(Figure 2a) and tibia (Figure 2b) compared to control animals 
injected with vehicle only. As experimental controls, we chose 
Cyp24a1 and Fgf23. Renal transcripts of Cyp24a1, the gene 
encoding the vitamin D inactivating enzyme cytochrome P450 
24a1, were upregulated by 1,25(OH)2-vitamin D3 compared to 
vehicle (Figure 2c). In addition, expression of Fgf23 in the tibia 
was increased by 1,25(OH)2-vitamin D3 (Figure 2d).
3.2 | Memo1 is not regulated by 
dietary calcium
Next, we determined the effect of varying dietary calcium 
content for 7 days on Memo1 gene expression. RNA was 
obtained from a previous experiment performed in our lab 
(366). In the kidney (Figure 3a) and in the tibia (Figure 3b) 
of these mice exposed to three different calcium-containing 
diets (0.17%, 0.82%, and 1.69%), no change in Memo1 gene 
expression was observed. A 2.5-fold increase in gene ex-
pression of Casr encoding the calcium-sensing receptor in 
the bone upon dietary calcium restriction serves as an ex-
perimental control for the dietary intervention and was re-
ported for the samples we used in (O'Seaghdha et al., 2013).
3.3 | Memo1 is not regulated by 
dietary phosphate
We investigated the influence of different systemic phos-
phate loads on Memo1 expression. We showed that different 
F I G U R E  1  Transcriptional responses 
to 1,25(OH)2-vitamin D3 in MLO-Y4 
osteocyte-like cells. 1,25(OH)2-vitamin D3 
treatment significantly increased Cyp24a1 
transcripts (a), decreased Phex transcripts 
(b), increased Rankl transcripts (c), 
decreased Bglap (osteocalcin) transcripts 
(d), and decreased Memo1 (e) transcripts 
in MLO-Y4 cells. n = 6 per condition, 
*p < .05 (t test)
   | 5 of 9MOOR and BOnnY
dietary phosphate contents (0.2%, 0.8%, 1.5%) did not signifi-
cantly affect Memo1 transcript levels in kidney (Figure 4a) or 
in the tibia (Figure 4b). As an experimental control gene we 
used renal transcripts of Slc34a3 encoding sodium-dependent 
phosphate transporter type 2c (NaPi2c). Renal Slc34a3 was 
increased, as expected, under low phosphate and decreased 
under high phosphate diets (Figure 4c).
3.4 | Memo1 unchanged by PTH
To determine the effect of PTH on Memo1, human PTH frag-
ments 1–34 were subcutaneously injected to wild-type mice, 
and the animals were euthanized after 2 hr. Memo1 gene ex-
pression in kidney (Figure 5a) or in tibia (Figure 5b) remained 
unchanged upon PTH treatment. Transcripts of Cyp27b1, the 
gene coding for the renal vitamin D activating enzyme cy-
tochrome P450 27b1 were increased upon PTH compared to 
NaCl 0.9%-treated controls (Figure 5c).
3.5 | Memo1 unchanged by estradiol
As sex hormones exert effects on both renal calcium trans-
port proteins (van Abel et al., 2002) and FGF23 in the bone 
(Carrillo-Lopez et al., 2009), we tested if Memo1 is a tar-
get gene induced by estradiol. We subcutaneously injected 
17β-estradiol once daily over 5 days. This induced the ex-
pression of the control gene F3 encoding coagulation factor 
III (Figure 6c), but gene expression of Memo1 in the kidney 
(Figure 6a) and in the bone (Figure 6b) both remained un-
changed compared to mice injected with vehicle.
F I G U R E  2  Memo1 transcripts 
were not changed by 1,25(OH)2-vitamin 
D3 treatment in wild-type mice. Memo1 
transcripts were assessed in kidney (a) and 
tibia (b) and were indifferent 6 hr after 
1,25(OH)2-vitamin D3 injection, whereas 
renal Cyp24a1 transcripts were over  
10-fold increased in comparison to vehicle 
control (c). Fgf23 gene expression in 
tibia was increased by 1,25(OH)2-vitamin 
D3 compared to vehicle (d). n = 5 per 
condition, *p < .05 (Mann–Whitney U test)
F I G U R E  3  Memo1 transcript levels were not influenced by varying dietary calcium contents. Memo1 transcripts in kidney (a) and tibia (b) 
were not significantly affected by different dietary calcium intakes; n = 5 per diet (Kruskal–Wallis tests). Calcium-sensing receptor increased 2.5-
fold in bone of mice on 0.17% calcium diet published in (O'Seaghdha et al., 2013) using the same samples serves as an experimental control
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To summarize, we found a small but significant decrease 
in Memo1 expression upon 1,25(OH)2-vitamin D3 expo-
sure in vitro, but we failed to detect any major regulation of 
Memo1 transcript abundance upon mineral load or calciotro-
pic hormone treatment in vivo.
4 |  DISCUSSION
MEMO1 is expressed in the kidney where it plays an intra-
renal role in the regulation of calcium transporters (Moor, 
Haenzi, et al., 2018). In the bone, MEMO1 is expressed in 
all cell types (Moor, Ramakrishnan, et al., 2018), but its 
precise bone-specific function remains elusive.
Here we tested the hypothesis whether Memo1 is regulated by 
key players in mineral homeostasis such as calciotropic hormones 
or dietary calcium or phosphate. As a readout, we chose Memo1 
gene expression in an osteocyte-like cell line, and in bone and kid-
ney tissues. For each intervention, an experimental control gene 
was assessed and revealed effects similar as shown before by others.
We observed that Memo1 gene expression was dimin-
ished in the osteocyte-like cells upon 1,25(OH)2-vitamin D3 
F I G U R E  4  Memo1 transcript levels 
were not affected by varying dietary 
phosphate contents. Memo1 transcripts 
abundance in kidney (a) and in tibia 
(b) were not significantly changed by 
dietary phosphate contents. Neither bone 
Memo1 (b). Renal Slc34a3 transcripts 
were used as an experimental control gene 
and were affected by dietary phosphate 
content (c). N = 5 per condition; *p < .05 
(Kruskal–Wallis test with Dunn's multiple 
comparisons correction)
F I G U R E  5  Memo1 gene expression 
remained unchanged upon PTH treatment 
in wild-type mice. Human PTH1-34 or 
NaCl 0.9% vehicle was injected 2 hr prior 
to dissection and transcripts of Memo1 in 
kidney (a) and tibia (b) were unchanged 
between experimental conditions. 
Transcripts of Cyp27b1 (c) were increased 
by PTH1-34. n = 6 per condition; ns, not 
significant; *p < .05 (Mann–Whitney U 
test). PTH, parathyroid hormone
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treatment. However, in bone and tissues, we failed to detect 
any effect on Memo1 by all interventions that we studied. 
This shows a major difference between Memo1 and the most 
studied contributors to mineral homeostasis. As examples in 
the kidney, Type II sodium-dependent phosphate cotrans-
porters are regulated by dietary phosphate supply (Bourgeois 
et al., 2013) and gene expression of Trpv5 encoding a renal 
calcium transport protein is controlled by 1,25(OH)2-vitamin 
D3 (Hoenderop et al., 2001). As examples in the bone, Fgf23 
expression is stimulated by 1,25(OH)2-vitamin D3 (Liu et al., 
2006) or PTH (Kawata et al., 2007), while dietary phosphate 
restriction or renal phosphate-wasting disorders reduce Fgf23 
expression (Ansermet et al., 2017; Schlingmann et al., 2016; 
Vervloet et al., 2011). Even intravenous calcium loading in 
rats increased Fgf23 expression in bone and hormone con-
centrations in the serum (Shikida et al., 2018).
This study contains some limitations: The current inter-
ventions were confined to the analysis of gene expression, but 
we did not directly assess Memo1 promoter activity using a 
reporter construct. Such an approach would more sensitively 
discriminate and would allow validating putative response 
elements in the Memo1 promoter. In addition, our in silico 
analysis of the presumed promoter sequence did not allow 
base mismatches compared to known response elements. 
However, we argue that a physiologically relevant the reg-
ulation of Memo1 gene expression, if present, should have 
been visible using the experimental approaches that were 
undertaken.
Further, we have assessed a single but physiologically rea-
sonable time point, and only a narrow selection of tissues and 
cells. In addition to bone and kidney, the intestine would be 
another major turnover place for minerals. Memo1 expression 
and potential regulation in healthy intestine have not been in-
vestigated so far. In colorectal cancer cells Memo1 promoter 
activity is increased in response to the transcription factors 
Aryl hydrocarbon receptor/ Aryl hydrocarbon receptor nu-
clear-translocator complex, indicating some intestinal disease 
relevance (Bogoevska et al., 2017).
Another limitation is the fact that we investigated only 
mice of male sex as to simplify experimental planning, reduc-
tion of mice numbers used, and as to reproduce the hormone 
injection protocols in the cited references, including the estra-
diol injection protocol (van Abel et al., 2002). Future experi-
ments should be conducted with both sexes independently to 
allow the detection of sex-specific effects.
Finally, as Memo is a redox enzyme with incompletely 
understood reaction partners and substrates (MacDonald 
et al., 2014), an assessment of posttranslational regulation 
such as by the oxidative modification of MEMO1 protein, 
subcellular localization, or changes in its putative enzy-
matic activity may be helpful to investigate a regulation of 
Memo1.
To conclude, besides a minor effect in bone cells stimu-
lated with 1,25(OH)2-vitamin D3, we did not detect a major 
regulation of Memo1 gene expression upon minerals and cal-
ciotropic stimuli in bone and kidney, two organs relevant for 
mineral homeostasis. Further studies inquiring the regulation 
of this and similar genes may contribute to the understanding 
of the regulation of mineral homeostasis in health and renal 
and bone diseases.
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